TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00121186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 30 mg/m\^2 on days -6 to -2 (2-6 days before transplant).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 70 mg/m\^2 on days -3 and -2 (2-3 days before transplant).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 5 mg/m\^2 on days 1, 3, and 7 post-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: 0.03 mg/kg bid on days -3 to 100 post-transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: if donor bone marrow stem cells are harvested

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: if donor peripheral blood stem cells are harvested
Study: NCT01557907

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous delivery via Medtronic Quick-Set
Description: Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradermal delivery via the BD Research Catheter Set
Description: Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
Study: NCT01013857

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health coaching
Description: Calling patients every week to discuss medication adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching plus home titration
Description: Calling patients every week and intensifying medications if appropriate based on physician-created algorithm
Study: NCT02430883

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Intrarenal Surgery
Description: endoscopic treatment of kidney stones with flexible renoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Intrarenal Surgery
Description: endoscopic treatment of kidney stones with flexible renoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Intrarenal Surgery
Description: endoscopic treatment of kidney stones with flexible renoscopy
Study: NCT04067804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic Adaptation Process
Description: The Dynamic Adaptation Process draws from implementation science frameworks and methods, including the Exploration, Preparation, Implementation, and Sustainment model, to organize planning and implementation activities. The Dynamic Adaptation Process is a structured methodology designed to integrate new interventions within complex systems, such as schools.
Study: NCT02264327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Simulator (SIM)
Description: The interactive, case-based, multiplayer web-based game allows service providers to deepen their skills in Motivational Interviewing (MI), a widely recognized evidence-based practice that supports people to make positive behavior changes related to health, wellness, mental illness, and addiction.The SIM will have three arenas for play, so that users can practice more advanced MI skills and include: Single Player, Two Player, and Advanced Free play. The SIM is equipped with multiple story-lines and characters to keep learners engaged over time and to provide practice on diverse case scenarios, making the Sim relevant to a wide audience. Lastly the SIM will provide an opportunity for feedback from peers and MI experts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing eBook (eBook)
Description: The Phase I research team developed a 69-page eBook as a credible online comparator that presents information comparable to that included in the Sim, but without the interactive, role-playing, peer learning functionalities embodied in the Sim. Developed in Hyperlink Markup Language, the eBook presented MI skills, followed by transcripts of effective and not-effective samples of MI from the Sim itself. The e-Book includes the story-lines along with sample dialogue and expert feedback on MI skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing Training (MI Training)
Description: The training intervention consists of a free two-day standardized Motivational Interviewing (MI) training provided by experienced MI trainers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Training (MI Training)
Description: The training intervention consists of a free two-day standardized Motivational Interviewing (MI) training provided by experienced MI trainers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing Training (MI Training)
Description: The training intervention consists of a free two-day standardized Motivational Interviewing (MI) training provided by experienced MI trainers.
Study: NCT00738387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA404
Description: 1800 mg/m2 of ASA404 i.v. on day 1 of each 21 day cycle
Study: NCT02430883

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Intrarenal Surgery
Description: endoscopic treatment of kidney stones with flexible renoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Intrarenal Surgery
Description: endoscopic treatment of kidney stones with flexible renoscopy
Study: NCT01931163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study: NCT00738387

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo i.v. on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days
Study: NCT04678388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: 1 Cap., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: 1 Cap., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: 1 Cap., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: 1 Cap., single oral administration under fasting condition
Study: NCT01641367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Participants were administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Participants were administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Participants were administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food
Study: NCT04678388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: 1 Cap., single oral administration under fasting condition
Study: NCT01641367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)
Description: LPV/r and ATV/r were the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC were the most frequent NRTI backbones. Cohort A did not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available
Description: For Cohort D, in many situations a participant received the same regimen that patients are getting in Cohorts B and C if that was the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there were no further drug options beyond the available study drugs).
Study: NCT04678388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: 1 Cap., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: 1 Tab., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: 1 Tab., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: 1 Tab., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: 1 Tab., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: 1 Tab., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: 1 Tab., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: 1 Tab., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: 1 Tab., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: 1 Tab., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: 1 Tab., single oral administration under fasting condition
Study: NCT00738387

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days
Study: NCT01532401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium chloride
Description: sodium chloride 500mg
Study: NCT04678388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: 1 Tab., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: 1 Tab., single oral administration under fasting condition
Study: NCT04028141

Intervention type: DRUG
Intervention: Procedural sedation with ketofol in a 1 on 4 ratio
Description: The participant was brought to a zone where advanced life support could be optimally administered and where all necessary drugs and materials for treatment of complications are present. Oxygen saturation, continuous electrocardiogram, intermittent blood pressure measurement (every 2 minutes) and capnography were applied. A 20 gauge intravenous line was inserted. The participant was placed in semi-recumbent position and was given oxygen for at least 3 minutes through a non-rebreather mask unless contra-indications applied.~Ketofol 1 on 4 was prepared by mixing 1ml of ketamine (50mg) and 20ml of propofol (200mg) in a single syringe. It was administrated as a loading dose of 1ml/10kg, corresponding to 0,952mg/kg propofol and 0,238mg/kg ketamine, and followed by titration in aliquots of 0,5ml/10kg every 1 to 2 minutes until desired depth of sedation was achieved, and then every 3-5 minutes to retain the desired depth of sedation. The loading dose was halved if above 65 years.
Study: NCT01641367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC adherence versus SOC+CPI adherence
Description: * not participating in the adherence randomization; OR~* randomized to SOC adherence; OR~* randomized to SOC+CPI adherence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC adherence versus SOC+CPI adherence
Description: * not participating in the adherence randomization; OR~* randomized to SOC adherence; OR~* randomized to SOC+CPI adherence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC adherence versus SOC+CPI adherence
Description: * not participating in the adherence randomization; OR~* randomized to SOC adherence; OR~* randomized to SOC+CPI adherence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC adherence versus SOC+CPI adherence
Description: * not participating in the adherence randomization; OR~* randomized to SOC adherence; OR~* randomized to SOC+CPI adherence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC adherence versus SOC+CPI adherence
Description: * not participating in the adherence randomization; OR~* randomized to SOC adherence; OR~* randomized to SOC+CPI adherence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC adherence versus SOC+CPI adherence
Description: * not participating in the adherence randomization; OR~* randomized to SOC adherence; OR~* randomized to SOC+CPI adherence.
Study: NCT01782781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine, ketorelac and epinephrine
Description: Active group
Study: NCT01532401

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Methylcellulose crystalline
Description: Methylcellulose 37 ml
Study: NCT01683396

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab
Description: Solution for subcutaneous injection
Study: NCT00423878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Continued treatment with the medication risperidone for schizophrenia for up to 6 months in study
Study: NCT03482492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol iv
Study: NCT01782781

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group
Study: NCT02607514

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: hyperthermic yoga
Description: heated yoga, 90-minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hyperthermic yoga
Description: heated yoga, 90-minutes
Study: NCT01528605

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zeaxanthin plus lutein
Description: one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks
Study: NCT00136149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implants
Description: Immediate implants are used.
Study: NCT02795728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of the GIC based sealant
Description: Application of the GIC based sealant was carried out according to the manufacturer's instructions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin based sealant
Description: Application of the resin based sealant on the occlusal surfaces was carried out as per the manufacturer s recommendations.
Study: NCT03221595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Operative
Description: This operation involves reducing and providing rigid fixation of displaced rib fractures with permanent plates or splints
Study: NCT04724954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation Therapy on Experimental Robotic Table and standard of care
Description: Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). They will also receive Standard of Care rehabilitation

Intervention type: GENETIC
Group type: SHAM_COMPARATOR
Intervention: Rehabilitation Therapy as part of Standard of Care (Control)
Description: Control group will receive Standard of Care training only
Study: NCT04632251

Intervention type: DEVICE
Group type: OTHER
Intervention: SENSEI®
Description: SENSEI® laparoscopic tethered gamma probe is an intra-operative laparoscopic gamma probe system
Study: NCT03002051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided drainage
Description: * Ultrasonographic evaluation of the lesion by linear echoendoscope and positioning for transenteric puncture in shortest distance between enteric wall and the target lumen for drainage.~* EUS-guided transenteric puncture by using a 19-gauge needle followed by placement of a 0.035 or 0.025-inch guidewire into the target lumen.~* After the needle is removed in remaining the guidewire, the tract is dilated over the guidewire by using bougie dilator or needle type cystotome (Endoflex, Voerde, Germany). And then, the tract may be more dilated by using balloon catheter (4-mm).~* After dilation of the tract, stent delivery system is inserted over the guidewire into the target lumen.~* After complete deployment of the distal flange under EUS and fluoroscopic guidance into the target lumen, proximal retraction of the delivery system until the blue mark on the handle of the introducer is seen. And then, the proximal flange is deployed slowly under endoscopic guidance.
Study: NCT00769847

Intervention type: PROCEDURE
Intervention: Endoscopic strip craniectomy
Description: Surgery
Study: NCT00688480

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule, orally for 9 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 300 mg once/day orally, 9 months
Study: NCT00994448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion SR 150mg tabs
Description: Bupropion SR 150mg tabs (Zyban) twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: One placebo tablet twice daily
Study: NCT01323075

Intervention type: PROCEDURE
Intervention: Truncal block
Description: Patients will have a truncal block during hand or wrist surgery.

Intervention type: PROCEDURE
Intervention: Truncal block
Description: Patients will have a truncal block during hand or wrist surgery.

Intervention type: PROCEDURE
Intervention: Truncal block
Description: Patients will have a truncal block during hand or wrist surgery.
Study: NCT04155515

Intervention type: DRUG
Group type: OTHER
Intervention: TG-2349
Description: TG-2349 400mg

Intervention type: DRUG
Group type: OTHER
Intervention: TG-2349
Description: TG-2349 400mg

Intervention type: DRUG
Group type: OTHER
Intervention: DAG181
Description: DAG181 200mg

Intervention type: DRUG
Group type: OTHER
Intervention: DAG181
Description: DAG181 200mg

Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: Ribavirin 1000mg/1200mg

Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: Ribavirin 1000mg/1200mg
Study: NCT02759120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy: Co-trimoxazole or Doxycycline
Description: 160mg trimethoprim/800mg sulfamethoxazole (double strength co-trimoxazole) twice daily plus folic acid 5 mg daily OR doxycycline 100mg once daily if weight \< 50 kilograms or 100mg twice daily if weight \> 50 kilograms for up to 36 months

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention: Standard of Care
Description: Standard of care
Study: NCT04415606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuikClot Control+
Description: Non-absorbable, sterile, X-ray detectable non-woven dressing impregnated with kaolin.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: QuikClot Control+
Description: Non-absorbable, sterile, X-ray detectable non-woven dressing impregnated with kaolin.
Study: NCT00937417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: proteomic profiling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT02779842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY 987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. formulation number SR15-39-Z12-002.
Study: NCT04653779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin 5mg/Metformin 1000mg
Description: Size reduction of a tablet formulation
Study: NCT02509065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm for type 1 diabetes patients will deliver insulin and glucagon. The 100 mg/dl arm for type 2 diabetes patients will deliver just insulin. The 115 mg/dl arm will deliver insulin and glucagon. The 120 mg/dl arm will deliver just insulin. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl and 110 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm for type 1 diabetes patients will deliver insulin and glucagon. The 100 mg/dl arm for type 2 diabetes patients will deliver just insulin. The 115 mg/dl arm will deliver insulin and glucagon. The 120 mg/dl arm will deliver just insulin. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl and 110 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm for type 1 diabetes patients will deliver insulin and glucagon. The 100 mg/dl arm for type 2 diabetes patients will deliver just insulin. The 115 mg/dl arm will deliver insulin and glucagon. The 120 mg/dl arm will deliver just insulin. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl and 110 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm for type 1 diabetes patients will deliver insulin and glucagon. The 100 mg/dl arm for type 2 diabetes patients will deliver just insulin. The 115 mg/dl arm will deliver insulin and glucagon. The 120 mg/dl arm will deliver just insulin. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl and 110 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm for type 1 diabetes patients will deliver insulin and glucagon. The 100 mg/dl arm for type 2 diabetes patients will deliver just insulin. The 115 mg/dl arm will deliver insulin and glucagon. The 120 mg/dl arm will deliver just insulin. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl and 110 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.